Cardiac safety analysis of anti-her2-targeted therapy in early breast cancer

HIGHLIGHTS

• who: Li Zhang from the combined with pertuzumab for more than half a year in Tianjin Medical University have published the research work: Cardiac safety analysis of anti-HER2-targeted therapy in early breast cancer, in the Journal: Scientific Reports Scientific Reports
• what: The cardiac safety of anti-HER2-targeted therapy for early breast cancer was encouraging.
• how: The authors declare that the study was conducted in accordance with the principles of the World Medical Association Declaration of Helsinki "Ethical Principles for Medical Research Involving Human Subjects" (revised in October 2013). Next the . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.